# Supplementary

|  |  |  |  |
| --- | --- | --- | --- |
| SCT | Two-way ANOVA | F (dFn, dFd) | P value |
| *2 weeks* | CMS | F (2,62) =50.200 | p=0.000 |
| time  | F (2,62) =47.700 | p=0.000 |
| time X CMS | F (4,62) =51.600 | p=0.000 |
|  | One-way ANOVA | F (dFn, dFd) | P value |
| *vulnerable-recovery* | time X CMS | F (5, 139) =46,062 | p=0.000 |

# Supplementary table 1: One/two-way ANOVA analysis of *the sucrose consumption test with repeated measures.*

|  |  |  |  |
| --- | --- | --- | --- |
| CORT | Two-way ANOVA | F (dFn, dFd) | P value |
| *2 weeks* | CMS | F (3,57) =2.917 | p=0.043 |
| ARS | F (1,57) =4.780 | p=0.033 |
| CMS X ARS | F (3,57) =1.719 | p=0.174 |

# Supplementary table 2: Two-way ANOVA analysis of *the corticosterone plasma levels.*

|  |  |  |  |
| --- | --- | --- | --- |
| IEGs | Two-way ANOVA | F (dFn, dFd) | P value |
| vHip |
| *Arc* | CMS | F (1,62) =7.557 | p=0.008 |
| ARS | F (1,62) =25.643 | p=0.000 |
| CMS X ARS | F (1,62) =0,057 | p=0.813 |
| *Cfos* | CMS | F (1,63) =0.253 | p=0.617 |
| ARS | F (1,63) =152.978 | p=0.000 |
| CMS X ARS | F (1,63) =13.605 | p=0.000 |
| dHip |
| *Arc* | CMS | F (1,62) =1.279 | p=0.263 |
| ARS | F (1,62) =46.879 | p=0.000 |
| CMS X ARS | F (1,62) =0.184 | p=0.670 |
| *Cfos* | CMS | F (1,56) =0.982 | p=0.326 |
| ARS | F (1,56) =71.349 | p=0.000 |
| CMS X ARS | F (1,56) =2.969 | p=0.091 |
| Amy |
| *Arc* | CMS | F (1,62) =1.125 | p=0.293 |
| ARS | F (1,62) =110.518 | p=0.000 |
| CMS X ARS | F (1,62) =0.463 | p=0.499 |
| *Cfos* | CMS | F (1,63) =0.806 | p=0.373 |
| ARS | F (1,63) =203.879 | p=0.000 |
| CMS X ARS | F (1,63) =1.361 | p=0.248 |
| Pfc |
| *Arc* | CMS | F (1,54) =4.361 | p=0.042 |
| ARS | F (1, 54) =49.042 | p=0.000 |
| CMS X ARS | F (1, 54) =0.223 | p=0.639 |
| *Cfos* | CMS | F (1, 50) =13.110 | p=0.001 |
| ARS | F (1, 50) =10.238 | p=0.002 |
| CMS X ARS | F (1, 50) =0.165 | p=0.687 |
| ERGs | Two-way ANOVA | F (dFn, dFd) | P value |
| vHip |
| *Gadd45b* | CMS | F (1,63) =0.472 | p=0.495 |
| ARS | F (1,63) =45.706 | p=0.000 |
| CMS X ARS | F (1,63) =8.808 | p=0.004 |
| *Sgk1* | CMS | F (1,63) =8.398 | p=0.005 |
| ARS | F (1,63) =43.058 | p=0.000 |
| CMS X ARS | F (1,63) =8.697 | p=0.005 |
| *Dusp1* | CMS | F (1,63) =3.741 | p=0.058 |
| ARS | F (1,63) =57.788 | p=0.000 |
| CMS X ARS | F (1,63) =3.235 | p=0.077 |
| *Nr4a1* | CMS | F (1,59) =0.299 | p=0.587 |
| ARS | F (1,59) =56.048 | p=0.000 |
| CMS X ARS | F (1,59) =0.496 | p=0.484 |
| dHip |
| *Gadd45b* | CMS | F (1,63) =0.607 | p=0.439 |
| ARS | F (1,63) =53.176 | p=0.000 |
| CMS X ARS | F (1,63) =2.598 | p=0.112 |
| *Sgk1* | CMS | F (1,63) =7.272 | p=0.009 |
| ARS | F (1,63) =39.025 | p=0.000 |
| CMS X ARS | F (1,63) =3.648 | p=0.061 |
| *Dusp1* | CMS | F (1,63) =0.017 | p=0.896 |
| ARS | F (1,63) =50.278 | p=0.000 |
| CMS X ARS | F (1,63) =4.765 | p=0.033 |
| *Nr4a1* | CMS | F (1,62) =1.756 | p=0.190 |
| ARS | F (1,62) =34.873 | p=0.000 |
| CMS X ARS | F (1,62) =0.180 | p=0.673 |
| Amy |
| *Gadd45b* | CMS | F (1,63) =1.477 | p=0.229 |
| ARS | F (1,63) =72.132 | p=0.000 |
| CMS X ARS | F (1,63) =5.547 | p=0.022 |
| *Sgk1* | CMS | F (1,63) =6.363 | p=0.014 |
| ARS | F (1,63) =39.603 | p=0.000 |
| CMS X ARS | F (1,63) =8.424 | p=0.005 |
| *Dusp1* | CMS | F (1,63) =0.834 | p=0.365 |
| ARS | F (1,63) =68.774 | p=0.000 |
| CMS X ARS | F (1,63) =2.606 | p=0.112 |
| *Nr4a1* | CMS | F (1,62) =0.299 | p=0.587 |
| ARS | F (1,62) =113.920 | p=0.000 |
| CMS X ARS | F (1,62) =0.627 | p=0.432 |
| PFC |
| *Gadd45b* | CMS | F (1,54) =5.073 | p=0.029 |
| ARS | F (1,54) =52.389 | p=0.000 |
| CMS X ARS | F (1,54) =0.275 | p=0.603 |
| *Sgk1* | CMS | F (1,54) =1.008 | p=0.320 |
| ARS | F (1,54) =11.647 | p=0.001 |
| CMS X ARS | F (1,54) =1.527 | p=0.222 |
| *Dusp1* | CMS | F (1,55) =3.043 | p=0.087 |
| ARS | F (1,55) =11.752 | p=0.001 |
| CMS X ARS | F (1,55) =0.481 | p=0.491 |
| *Nr4a1* | CMS | F (1,58) =3.644 | p=0.061 |
| ARS | F (1,58) =42.043 | p=0.000 |
| CMS X ARS | F (1,58) = 1.997 | p=0.163 |

# Supplementary table 3: Two-way ANOVA Analysis of *IRGs and ERGs* mRNA levels in the ventral hippocampus (vHip), dorsal hippocampus (dHip), amygdala (Amy) and prefrontal cortex (Pfc) of chronically stressed rats exposed to 1 hour of acute restraint stress (ARS).

|  |  |  |  |
| --- | --- | --- | --- |
| IEGsZ-activation | Two-way ANOVA | F (dFn, dFd) | P value |
| vHip | CMS | F (1,62) =1.350 | p=0.2678 |
| ARS | F (1,62) =132 | p=0.000 |
| CMS X ARS | F (1,62) =1.770 | p=0.1639 |
| dHip | CMS | F (1,56) =0.693 | p=0.5609 |
| ARS | F (1,56) =104 | p=0.000 |
| CMS X ARS | F (1,56) =1.300 | p=0.2846 |
| Amy | CMS | F (1,62) =1.360 | p=0.2643 |
| ARS | F (1,62) =278 | p=0.000 |
| CMS X ARS | F (1,62) =1.840 | p=0.61508 |
| Pfc | CMS | F (1,55) =5.07 | p=0.0040 |
| ARS | F (1,55) =47.3 | p=0.000 |
| CMS X ARS | F (1,55) =0.491 | p=0.6899 |
| ERGs Z-activation | Two-way ANOVA | F (dFn, dFd) | P value |
| vHip |
| vHip | CMS | F (1,59) =4.900 | p=0.004 |
| ARS | F (1, 59) =135 | p=0.000 |
| CMS X ARS | F (1, 59) =8.840 | p=0.000 |
| dHip | CMS | F (1,63) =1 | p=0.084 |
| ARS | F (1,63) =85.700 | p=0.000 |
| CMS X ARS | F (1,63) =2.330 | p=0.398 |
| Amy | CMS | F (1,62) =0.740 | p=0.532 |
| ARS | F (1,62) =170 | p=0.000 |
| CMS X ARS | F (1,62) =4.940 | p=0.004 |
| Pfc | CMS | F (1,59) =3.2 | p=0.028 |
| ARS | F (1,59) =67 | p=0.000 |
| CMS X ARS | F (1,59) =3.8 | p=0.014 |

# Supplementary table 4: Two-way ANOVA Analysis of the Z activation of the *IRGs and ERGs* mRNA levels in the ventral hippocampus (vHip), dorsal hippocampus (dHip), amygdala (Amy) and prefrontal cortex (Pfc) of chronically stressed rats exposed to 1 hour of acute restraint stress (ARS).